p73 loss triggers conversion to squamous cell carcinoma reversible upon reconstitution with TAp73α

Cancer Research

Volumn 67, Issue 16, 2007, Pages 7723-7730

  Johnson, Jodi ^a,b   Lagowski, James ^a   Sundberg, Alexandra ^a   Lawson, Sarah ^a   Liu, Yuangang ^a   Kulesz Martin, Molly ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; PROTEIN P73; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CONTROLLED STUDY; DNA DAMAGE; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; KERATINOCYTE; MEMBRANE RECONSTITUTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DNA-BINDING PROTEINS; KERATINOCYTES; MICE; MICE, INBRED BALB C; NUCLEAR PROTEINS; PROTEIN ISOFORMS; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 34548039448     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1195     Document Type: Article

References (50)

1. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004;25:177-81.
2. Irwin MS, Kaelin WG, Jr. Role of the newer p53 family proteins in malignancy. Apoptosis 2001;6:17-29.
3. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004;2:371-86.
4. Slade N, Zaika AI, Erster S, Moll UM. ΔNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death Differ 2004;11:357-60.
5. Rocco JW, Ellisen LW. p63 and p73: life and death in squamous cell carcinoma. Cell Cycle 2006;5:936-40.
6. Rocco JW, Leong CO, Kuperwasser N, Deyoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006;9:45-56.
7. Frasca F, Vella V, Aloisi A, et al. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 2003;63:5829-37.
8. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 downregulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001;21:1874-87.
9. Strano S, Munarriz E, Rossi M, et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 2000;275:29503-12.
10. Faridoni-Laurens L, Bosq J, Janot F, et al. p73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63? Oncogene 2001;20:5302-12.
11. Araki D, Uzawa K, Watanabe T, et al. Frequent allelic losses on the short arm of chromosome 1 and decreased expression of the p73 gene at 1p36.3 in squamous cell carcinoma of the oral cavity. Int J Oncol 2002;20:355-60.
12. Cai YC, Yang GY, Nie Y, et al. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis 2000;21:683-9.
13. Nenutil R, Ceskova P, Coates PJ, Nylander K, Vojtesek B. Differential expression of p73α in normal ectocervical epithelium, cervical intraepithelial neoplasia, and invasive squamous cell carcinoma. Int J Gynecol Pathol 2003;22:386-92.
14. Kamiya M, Takeuchi Y, Katho M, Yokoo H, Sasaki A, Nakazato Y. Expression of p73 in normal skin and proliferative skin lesions. Pathol Int 2004;54:890-5.
15. Ferru A, Denis S, Guilhot J, et al. Expression of TAp73 and ΔNp73 isoform transcripts in thyroid tumours. Eur J Surg Oncol 2005;32:228-30.
16. Ahomadegbe JC, Tourpin S, Kaghad M, et al. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. Oncogene 2000;19:5413-8.
17. Koga F, Kawakami S, Fujii Y, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003;9:5501-7.
18. Puig P, Capodieci P, Drobnjak M, et al. p73 Expression in human normal and tumor tissues: loss of p73α expression is associated with tumor progression in bladder cancer. Clin Cancer Res 2003;9:5642-51.
19. Masuda N, Kato H, Nakajima T, et al. Synergistic decline in expressions of p73 and p21 with invasion in esophageal cancers. Cancer Sci 2003;94:612-7.
20. Muller M, Schilling T, Sayan AE, et al. TAp73/ΔNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005;12:1564-77.
21. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006;13:962-72.
22. Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005;7:363-73.
23. Keyes WM, Vogel H, Koster MI, et al. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci U S A 2006;103:8435-40.
24. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-13.
25. Cui R, He J, Mei R, et al. Expression of p53, p63, and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus. Biochem Biophys Res Commun 2005;336:339-45.
26. De Laurenzi V, Rossi A, Terrinoni A, et al. p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem Biophys Res Commun 2000;273:342-6.
27. Johnson J, Lagowski J, Sundberg A, Kulesz-Martin M. p53 family activities in development and cancer: relationship to melanocyte and keratinocyte carcinogenesis. J Invest Dermatol 2005;125:857-64.
28. Knights CD, Liu Y, Appella E, Kulesz-Martin M. Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification. J Biol Chem 2003;278:52890-900.
29. Kulesz-Martin MF, Lisafeld B, Huang H, Kisiel ND, Lee L. Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol Cell Biol 1994;14:1698-708.
30. Kulesz-Martin MF, Penetrante R, East CJ. Benign and malignant tumor stages in a mouse keratinocyte line treated with 7,12-dimethylbenz[a] anthracene in vitro. Carcinogenesis 1988;9:171-4.
31. Wu Y, Huang H, Miner Z, Kulesz-Martin M. Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53. Proc Natl Acad Sci U S A 1997;94:8982-7.
32. King KE, Ponnamperuma RM, Gerdes MJ, et al. Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis. Carcinogenesis 2006;27:53-63.
33. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
34. Stiewe T, Putzer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002;9:237-45.
35. Matsumoto H, Matsuyama H, Fukunaga K, Yoshihiro S, Wada T, Naito K. Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer. Br J Cancer 2004;91:1025-31.
36. Chen YK, Hsue SS, Lin LM. Immunohistochemical demonstration of p73 protein in the early stages of DMBA-induced squamous-cell carcinogenesis in hamster buccal pouch. Arch Oral Biol 2002;47:695-9.
37. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
38. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
39. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-8.
40. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-94.
41. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
42. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560-4.
43. Senoo M, Manis JP, Alt FW, McKeon F. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 2004;6:85-9.
44. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006;443:214-7.
45. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445:661-5.
46. Kastan MB. Wild-type p53: tumors can't stand it. Cell 2007;128:837-40.
47. Das S, Nama S, Antony S, Somasundaram K. p73 β-expressing recombinant adenovirus: a potential anticancer agent. Cancer Gene Ther 2005;12:417-26.
48. Rodicker F, Putzer BM. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res 2003;63:2737-41.
49. Sasaki Y, Morimoto I, Ishida S, Yamashita T, Imai K, Tokino T. Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application to gene therapy of colorectal cancer. Gene Ther 2001;8:1401-8.
50. Bell HS, Dufes C, O'Prey J, et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 2007;117:1008-18.